
Introduction/Aim: Neurofibromatosis type 1 is an autosomal dominant disorder whose pulmonary manifestations remain underrecognized in clinical practice. Previous reviews have focused on diffuse lung disease and pulmonary arterial hypertension, without addressing the broader spectrum of complications or explaining the relationship between diffuse lung disease and tobacco smoking. The aim of this review is to synthesize the literature, identify opposing viewpoints, and formulate recommendations for clinical practice. Methods: PubMed and Google Scholar databases were searched for the period 2016-2026. Cohort studies, literature reviews, and case reports were included and analyzed according to methodological rigor and clinical relevance. Results: Six clinical categories of pulmonary manifestations of neurofibromatosis type 1 were identified. Diffuse lung disease occurs in 10-20% of adult patients and has been confirmed as a primary genetic entity that smoking modifies but does not cause. Pulmonary arterial hypertension carries a five-year survival rate below 50% and a limited response to standard therapy. Spontaneous pneumothorax is underrecognized as an initial manifestation of the disease. Intrathoracic meningoceles, vascular complications, and neurofibromas with malignant transformation complete the spectrum of manifestations that previous reviews have not systematically addressed. Conclusion: Pulmonary manifestations of neurofibromatosis type 1 are prognostically more significant than traditionally described. Routine evaluation using multidetector computed tomography of the lungs, spirometry, measurement of pulmonary diffusing capacity, and echocardiography is recommended. A multidisciplinary approach is essential for timely diagnosis and treatment of these patients.
Hashimoto's thyroiditis is the most common cause of hypothyroidism and is frequently associated with reduced functional capacity, fatigue, and impaired quality of life, even in patients with well-controlled thyroid hormone status. In recent years, physical activity has increasingly been recognized as an important non-pharmacological strategy in the management of this condition. The aim of this paper was to describe the mechanisms through which physical activity may exert beneficial effects in individuals with HT, identify the key barriers to its implementation, and provide practical guidelines for exercise planning and prescription. Based on a review of the available literature and clinical experience, several physical, psychological, treatment-related, organizational, and professional barriers that may hinder participation in regular physical activity were identified. At the same time, the potential beneficial effects of exercise on thyroid function, body composition, cardiorespiratory fitness, and mental health were considered. This paper emphasizes the importance of a gradual and individualized approach, including monitoring individual responses to exercise and coordinating exercise with medical treatment. A combination of aerobic exercise, resistance training, and interval-based exercise is proposed as a practical model, with particular emphasis on variable-intensity interval training as a potentially effective and safe approach for this population. In conclusion, physical activity has considerable potential as an integral component of a comprehensive approach to the management of individuals with Hashimoto's thyroiditis. However, clearer exercise guidelines and better integration of physical activity into clinical practice are needed to facilitate its broader implementation.
In this paper, we provide a brief review of metformin-associated lactic acidosis in renal patients with stage 3 to 4 chronic kidney disease. A 70-year-old male patient is presented, who has been treated for type 2 diabetes for the past twenty years. Since he was taking high doses of metformin at home, without the supervision of his family or doctor, he was urgently admitted to the Nephrology Clinic of the Clinical Center of Montenegro in Podgorica, where diagnostics were immediately performed and the patient was included in hemodialysis, along with other symptomatic and conservative therapy. During hospitalization, the patient's general condition and laboratory analyses of nitrogenous substances and potassium improved. In our case, the patient's treatment with hemodialysis led to rapid correction of metabolic disorders and hemodynamic stabilization, and ultimately to recovery, so there was no need for his further hemodialysis treatment. The patient was discharged home in good general condition, and it can be concluded that timely diagnosis of metformin-associated lactic acidosis is of great importance for hemodialysis treatment, which successfully corrects a severe metabolic disorder. This case suggests the importance of early recognition and treatment of patients with lactic acidosis in diabetics and renal patients who are taking uncontrolled or inadequate metformin therapy for the treatment of type 2 diabetes.
Introduction. The Lazarus phenomenon or the Lazarus syndrome, as it is also known, refers to the spontaneous return of circulation after unsuccessful resuscitation. This is a rare phenomenon, but it can lead to very unpleasant situations in clinical practice, and depending on circumstances, may have legal implications. The frequency of this phenomenon is relatively low, however many clinicians report experiencing it, with a prevalence rate of up to 50% among intensive care and emergency medicine physicians. The Lazarus phenomenon was first described in 1982, in Finland. Several heterogeneous possible mechanisms have been proposed to explain its occurrence. Aims of paper is to highlight possibility of the Lazarus phenomenon occurrence, and to minimize the risk of oversight. The paper uses an anonymous survey to assess physicians' knowledge about the phenomenon. Methods. For the paper is used an anonymous survey, which is created at the Web-site app.surveyplanet.com. The survey contained just one question - Are you familiar with the Lazarus phenomenon, with suggested answers: 1 - yes, 2 - no. At the survey participated 134 internal medicine residents on Medical Faculty University of Belgrade. Results. Of 134 participants, 64 reported knowing about the phenomenon, while 70 did not have knowledge of its existence. Conclusion. Number of physicians who lack knowledge about the Lazarus phenomenon highlights the need for more intensive education at all educational level.
Uvod/Cilj:Cilj rada je da predstavi metodološki okvir za desetogodišnje predviđanje multimorbiditeta pomoću generativnog, sekvencijalnog modela zasnovanog na transformer arhitekturi, uz potpuno oslanjanje na javno dostupne i sintetičke podatke, bez obrade identifikabilnih podataka pacijenata. Metode:Sprovedena je metodološka studija sa primarnom obukom i evaluacijom na Synthea sintetičkoj kohorti (≥100.000 zapisa), uz tehničke provere na MIMIC-III (de-identifikovani realni podaci intenzivne nege). Ishodi (≥1.000) su definisani mapiranjem ICD-10/ICD-10-CM kodova u PheCode kategorije. Model je transformer sa multitask izlazima (po jedan za svaki cilj) i vremenskim ugradnjama, sa evaluacijom diskriminacije (AUPRC, AUROC), kalibracije (Brier, intercept/nagib) i kliničke korisnosti (Decision Curve Analysis). Sprovedene su analize osetljivosti i osnovne provere pravičnosti (pol, starost). Rezultati:Model je postigao najbolje rezultate u kardiometaboličkom i onkološkom domenu, umerene u respiratornim/bubrežnim, a skromnije u mentalnim/infektivnim ishodima. Kalibracija je bila dobra u srednjim opsezima rizika; DCA je pokazala pozitivnu neto korist u pragovima relevantnim za oportunistički skrining (≈5-15% desetogodišnjeg rizika). Analize osetljivosti potvrdile su stabilnost rang-performansi na promenama pragova retkosti i dužine istorije, bez dokaza o značajnom "label leakage"-u. Zaključak:Prikazan je reproducibilan i etički prihvatljiv pristup dugoročnoj višebolećinskoj prognozi rizika koristeći generativni transformer na javnim/sintetičkim skupovima. Ovaj "barometar zdravlja" može da podrži trijažu i personalizovanu prevenciju, uz preporuku obavezne eksterne validacije, lokalne re-kalibracije i nadzora pravičnosti pre kliničke primene.